Despite this, we believe that the frequency of pages sent to the wrong physician is too high and are taking steps to reduce the potential for these errors.
Report of a Case. In August 2006, a 39-year-old woman with rheumatoid arthritis (RA) was seen at the outpatient clinic for exacerbation of RA. In the previous few months, she had progressively swollen and painful joints, notably her wrists, knees, and feet. A review of her medical history revealed that in addition to an erosive, rheumatoid factor anticitrullinated protein antibody-positive RA since 1995 she had autoimmune hypothyroidism and diabetes mellitus type 1 since 1986. For these conditions she used long-acting (24 U/d) and short-acting (50 U/d) insulin and L-thyroxine (262.5 µg/d). Findings from physical examination were unremarkable except for polyarthritis (shoulders, elbows, wrists, knees, ankles, hands, and feet). Her RA disease activity score of 28 joints (DAS28) was 8.3 (low disease status, DAS28Ͻ3.2). Type 1 diabetes mellitus and hypothyroidism were in a well-controlled condition ( exogenous (eg, pituitary TSH production) and endogenous (eg, Graves disease) causes. Both exogenous (as TSH levels were decreased, with inflated thyroxine levels), and endogenous (such as Graves disease) causes of hyperthyroidism seemed unlikely in this long-standing overt hypothyroid patient. Neither the L-thyroxine dosage nor smoking habits were changed, and the patient's type 1 diabetes mellitus remained in a well-controlled condition (hemoglobin A 1c level of 6.5%). Another mechanism that may explain the incidence of hyperthyroidism is an increased activation of thyroid peroxidase (TPO), an enzyme catalyzing reactions for synthesis of T 3 and FT 4 . A plausible explanation for elevated TPO activity is a drop in the level of antibodies against TPO (TPOAbs) by rituximab-induced depletion of plasma cell precursors. Indeed, TPOAbs declined to undetectable levels (as measured with the Phadia ImmunoCAP System; Phadia AB, Phadia AB, Uppsala, Sweden) after 5 months of treatment (Figure, A) .
Comment. Autoimmune hypothyroidism is characterized by lymphocytic infiltration of the thyroid and the presence of thyroid autoantibodies (eg, TPOAbs). 1 Another autoimmune disease characterized by (synovial) lymphocytic infiltration is RA. Rituximab, a chimeric monoclonal antibody against CD20-positive B lymphocytes, is known to decrease synovial lymphocyte aggregates in patients with RA. 2 Our hypothyroid diabetic patient with RA developed hyperthyroidism 4 months after initiating rituximab therapy. This is remarkable because rituximab is a novel therapy for patients with Graves disease.
3 Interestingly, in NOD.H-2h4 mice exposed to sodium iodide-polluted water to induce spontaneous autoimmune thyroiditis, thyroid autoantibody responses could be reduced by B-cell depletion. Moreover, Blymphocyte depletion in this murine study resulted in diminished B-and T-lymphocyte infiltration of the thyroid, thereby inhibiting the development of spontaneous autoimmune thyroiditis. 4 In line with this study, our observation suggests that rituximab therapy may be beneficial for autoimmune hypothyroidism. Although this hypothesis needs confirmation in other studies, in daily clinical practice, clinicians should be aware of (transient) stimulation of thyroid function during rituximab therapy in overt hypothyroid patients. 
